Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechanistic study of itepekimab on airway inflammation in COPD (Phase 2a, open-label, two-part)
2021-001654-65Phase 2Active
- Sponsor
- Sanofi
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of itepekimab in chronic obstructive pulmonary disease (COPD), sponsored by Sanofi. Primary endpoint: Part A: Log2 relative change from baseline in gene expression in endobronchial biopsies at Week 12. Started Sep 2021; status: active.
02
Drugs
itepekimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2021-001654-65.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001654-65.